摘要：
隨著精準醫療（Precision Medicine）、個人化健康照護與人工智慧技術的快速發展，生物晶片（Biochip）已成為全球醫療科技創新的關鍵核心之一。此類技術結合微電子製程、微流體控制、光電感測與奈米材料等跨領域要素，能於微小晶片空間中完成樣本前處理、檢測與分析，具備高靈敏度、即時性與可攜性等特性，被廣泛應用於疾病診斷、藥物篩選及生理訊號監測。近年來，生醫晶片（Biomedical Chip）與生醫積體電路（Bio-IC）之整合，更推動智慧醫療與次世代診斷技術的加速發展，成為各國科研投資與產業政策的重點領域。
在此國際趨勢下，臺灣與日本分別憑藉其半導體製造優勢與精密製程技術，於生醫晶片領域展現高度潛力。臺灣具備與日本相近的法規與倫理環境、完善的臨床體系與豐富的臨床資料基礎，並擁有強勁的半導體產業鏈與跨領域整合能力；日本則長期累積於微流體技術、奈米結構設計與光電量測系統，並透過產學研協作推動生醫晶片的高靈敏度檢測與微型化應用。兩國在科研文化、技術基盤與醫療制度上的相似性，為建立策略性科研合作奠定基礎。
本研究以2021年至2025年間臺灣「政府研究資訊系統（GRB）」、日本「科學技術振興機構（JST）」與「科研費補助金（KAKEN）」資料庫所收入之科研計畫為主要資料來源，採系統性關鍵字分析與技術分類比對方法，旨在辨識兩國在生醫晶片領域之早期研究投入焦點與應用趨勢。同時藉由比較分析，探討雙方在生物感測、癌症檢測、AI醫療晶片等領域之互補性與合作契機，並提出未來台日科研合作的具體方向。
本研究期望透過跨國科研資料之實證比較，揭示臺日兩國在生醫晶片領域的創新潛能與技術協同效應，進而為政策制定者與科研機構提供參考依據，促進雙邊科技交流與資源整合，推動亞洲生醫科技創新的區域合作新模式。
With the rapid advancement of precision medicine, personalized healthcare, and artificial intelligence, biochips have emerged as a critical component of global medical technology innovation. These technologies integrate interdisciplinary elements including microelectronics fabrication, microfluidic control, optoelectronic sensing, and nanomaterials, enabling sample preprocessing, detection, and analysis within miniaturized chip platforms. Characterized by high sensitivity, real-time processing capabilities, and portability, biochips are extensively deployed in disease diagnostics, drug screening, and physiological signal monitoring. Recent integration of biomedical chips with bio-integrated circuits (Bio-ICs) has accelerated the development of smart healthcare and next-generation diagnostic technologies, making this domain a strategic priority for national research investment and industrial policy globally.
Within this international context, Taiwan and Japan have demonstrated substantial potential in the biochip sector, leveraging their respective strengths in semiconductor manufacturing and precision engineering. Taiwan possesses regulatory and ethical frameworks comparable to Japan's, alongside a well-established clinical infrastructure and comprehensive clinical data resources. Additionally, Taiwan maintains robust semiconductor supply chains and strong interdisciplinary integration capabilities. Japan has accumulated extensive expertise in microfluidic technologies, nanostructure design, and optoelectronic measurement systems, advancing high-sensitivity detection and miniaturized biochip applications through industry-academia-government collaboration. The convergence of research cultures, technological foundations, and healthcare systems between these two nations provides a solid basis for strategic research partnerships.
This study draws upon research projects funded between 2021 and 2025, as documented in Taiwan's Government Research Bulletin (GRB) database and Japan's databases from the Japan Science and Technology Agency (JST) and Grants-in-Aid for Scientific Research (KAKEN). Employing systematic keyword analysis and technological classification methodologies, the research identifies focal areas of early-stage research investment and application trajectories in the biochip domain across both nations. Through comparative analysis, the study examines complementarities and collaboration opportunities in biosensing, cancer diagnostics, and AI-enabled medical chips, proposing concrete directions for future Taiwan-Japan research cooperation.
Through empirical comparison of cross-national research data, this study aims to elucidate the innovative potential and technological synergies between Taiwan and Japan in the biochip field. The findings are intended to inform policymakers and research institutions, facilitating bilateral scientific exchange and resource integration while promoting novel models of regional cooperation for biomedical technology innovation in Asia.
